30 closest matches · ranked by relevance
Recurrent Melanoma · Stage IA Melanoma · Stage IB Melanoma
Primary: T Cell Immunity to gp100 Peptide and to E7 12-20 Papilloma Virus Peptide — 0.02; 0.01; 0.97; 0.98 % of CD8+ T cells — p=<.001
Acute Myeloid Leukemia · Myelodysplastic Syndrome
Primary: Number of Subjects With Unacceptable Toxicity — 1 Participants
Acute Lymphoblastic Leukemia · Non Hodgkins Lymphoma · Myelodysplastic Syndrome
Primary: Engraftment Rate After Transplant — 100; 100 percentage of participants
Hematological Malignancies
Primary: Overall Survival at 6 Months Post-transplant in Patients Receiving a Partially-matched Related Donor Allogeneic Transplant After Reduced-intensity Conditioning — 22…
Hemophagocytic Lymphohistiocytosis · X-Linked Lymphoproliferative Disorders · Chediak-Higashi Syndrome
Primary: Number of Subjects With Mixed Chimerism — 3; 8; 4 participants
Hairy Cell Leukemia
Primary: Number of Patients Who Obtain Partial Response/Complete Remission — 1; 5 Participants
EBV-induced Lymphomas · EBV-associated Malignancies · Transplant Patients With EBV Viremia at High Risk for Developing a Recurrent EBV Lymphoma
Primary: Objective Response Rate (ORR) — 68.0; 50.0; 16.0; 14.3 Percentage of participants
Leukemia, Myeloid, Acute · Leukemia, Lymphoblastic, Acute · Leukemia, Myelocytic, Chronic
Primary: Overall Recipient Survival at 6-month Post-relapse of Disease — 0; 4 participants
Hemophagocytic Lymphohistiocytoses
Primary: Mean Serum Concentration of Inflammatory Biomarker - C-X-C Chemokine Ligand 10 (CXCL10) — 2079.286; 15197.143 picogram/milliliter (pg/mL)
Leukemia, Acute Myelogenous (AML) · Leukemia, Acute Lymphocytic (ALL) · Leukemia, Chronic Myelogenous (CML)
Primary: Toxicity — 5 participants
Leukemia, Acute Lymphocytic (ALL) · Leukemia, Myeloid, Acute(AML) · Leukemia, Myeloid, Chronic(CML)
Primary: Event-free Survival (EFS) — 54.8 Percentage of participants
Blood Cancer · Leukemia · Graft Versus Host Disease
Primary: Engraftment of Haploidentical CD34+ Selected Blood Stem Cells in Older Patients or Those With Medical Co-morbidities Following Total Lymphoid Irradiation and…
Acute T-Cell Leukemia-Lymphoma
Primary: Overall Response Rate — 52 percentage of participants
Hemophagocytic Lymphohistiocytosis
Primary: Overall Survival — 25 Participants
T-LGL Lymphoproliferative Disorders
Primary: Number of Participants With Hematological Response After Three Months of Alemtuzumab — 15 Participants
Leukemia
Primary: Number of Participants With a Response to Alemtuzumab or Tocilizumab in Combination With Etoposide and Dexamethasone for the Treatment of Adult Patients With…
Hodgkin Disease · Non Hodgkin Lymphoma · Lymphoepithelioma
Primary: Dose Limiting Toxicity (DLT) Rate by the NCI Common Toxicity Criteria (CTCAE) v2.0 and the Method of Przepiorka et al (Protocol Appendix I) — 0; 0; 0; 0 proportion of…
Hemophagocytic Lymphohistiocytosis
Primary: Mean Serum Concentration of Inflammatory Biomarker - C-X-C Chemokine Ligand 10 (CXCL10) — 5040.638; 454.392 picogram/milliliter (pg/mL)
Hematologic Malignancy
Primary: Proportion of Patients Undergoing an Allo HCT Transplant Who Have a KIR Favorable Donor. — 23; 21 Participants
Lymphoma
Primary: Number of Participants With Absolute Neutrophil Count >= 500/Mcl for 3 Consecutive Measurements on Different Days and Platelet Count > 20,000/mm^3 With no Platelet…
Hemophagocytic Lymphohistiocytosis · Chronic Active Epstein-Barr Virus Infection · Chronic Granulomatous Disease
Primary: Percentage of Participants With Overall Survival (OS) — 80.4; 66.7 percentage of participants
Myelodysplastic Syndrome · Acute Lymphocytic Leukemia · Acute Myelogenous Leukemia
Primary: Percentage of B Cells at One Year Post-transplant in Participants Who Did/Did Not Receive Leuprolide Following Bone Marrow Transplant (BMT) — 22.1; 21.9; 14.3 percentage…
Leukemia · Lymphoma · HIV
Primary: Percentage of Participants With Non-Relapse Mortality — 0.0; 11.8; 18.3 percentage of participants
Acute Myeloid Leukemia · Acute Lymphocytic Leukemia · Myelodysplasia
Primary: One-year Survival — 50 percentage of participants
HER2/Neu Positive · HLA-A2 Positive Cells Present · Stage IV Breast Cancer
Primary: Immune Response Measured by IFN-gamma Secreting PBMC Precursor Frequency by ELIspot and HLA-A2 Major Histocompatibility Complex Tetramer Analysis — 14; 4; 1; 16…
Chronic Graft-vs.-Host Disease
Primary: The Maximum Tolerated Dose (MTD) of a Four-week Course of Alemtuxumab in Chronic GVHD for Patients With an Incomplete Response to Steroids — 53 mg
Myelodysplastic Syndrome · Acute Myeloid Leukemia (AML) · Chronic Myeloid Leukemia (CML)
Primary: Cellular Immune Response — 4 participants
Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive · Acute Biphenotypic Leukemia · Acute Leukemia of Ambiguous Lineage
Primary: Chronic GVHD — 17; 20; 14; 17 Participants
Acute Lymphocytic Leukemia · Acute Myelogenous Leukemia · Burkitt's Lymphoma
Primary: Percentage of Participants With Progression Free Survival (PFS) — 35.0; 41.1 percentage of participants — p=0.4092
Acute Myeloid Leukemia · Acute Lymphoblastic Leukemia · Myelodysplastic Syndromes
Primary: Number of Participants Achieving Graft-versus-Host Disease-Free and Relapse-Free Survival (GRFS) Through 1 Year Post-Transplant — 4 Participants